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Background
The issue of neurodegeneration in schizophrenia is a con-
troversial one. The early descriptions by Kraepelin (1929)
pointing to neurodegenerative features were supported by
Alzheimer, who found evidence of cortical neuron loss
and by Southard, who described cerebral atrophy. During
the remainder of the past century though, the evidence
produced by several investigators rendered the involve-
ment of neurodegenerative processes highly unlikely,
with absence of gliosis being the major distinguishing fea-
ture of it from classical neurodegenerative disorders,
where gliosis is prominent. Thus all research work
reframed schizophrenia as a neurodevelopmenta disorder
and this is currently the prevailing hypothesis. The latter
promotes insight into several features of the disorder, but
nevertheless fails to account for a number of its cardinal
features, such as the protracted period of symptomatic
dormancy, the progressive clinical deteriration, affecting a
significant subgroup of patients and recent evidence for
changes in ventricular and cortical brain stuctures. New
datasuggest that a neurodegenerative perspective could
hold true filling the gaps of the neurodevelopmental
model. In our poster we critically review work from the
relevant domains and present the findings pertinent to a
neurodegenerative involvement
Materials and methods
We reviewed studies from clinical, neurocognitive, neu-
roimaging, and neuropathology domains. In particular,
from the clinical psychopathology and neurocognitive
domain we reviewed six papers (Addington and Adding-
ton JPN 2002, 27, Hambrecht et al. BJP 2002, 181, Hoff et
al. AJP 1999, 156 and 2000, 157, McGlashan Schiz Bull
1988, 14, Nopoulos et al. Schiz Res 1994, 14). From the
postmortem neuropathology domain we reviewed eight
papers (Benes et al. Arch Gen Psych 1991, 48, Biol Psych
2001, 50, Cotter et al. Brain Res Rev 2001, 55, Harrison
Brain 1999, 122, Pakkenberg Arch Gen Psych 1990, 47,
Young et al. Biol Psych 2000, 47, Mattson et al. Exp Neurol
1998, 153, Jarskog et al. Sciz Res 2001, 49). In the neu-
roimaging domain we reviewed three cross-sectional
structural studies (Gur et al. Arch Gen Psych 1998, 55,
Hulshoff Pol et al. AJP 2002, 159, Schlaepfer et al. AJP
1994, 151), five longitudinal studies (Cahn et al. Arch Gen
Psych 2002, 59, De Lisi et al. Psych Res Neuroim 1997, 74,
Gur et al. Arch Gen Psych 1998, 55, Lieberman et al. Biol
Psych 2001, 49, Mathalon et al. Arch Gen Psych 2001, 58),
two functional studies (Andreasen et al. Lancet 1997, 349,
Weinberger Arch Gen Psych 1987, 44), four spectroscopic
studies (Hinsberger et al. JPN 1997, 22, Pettergrew et al.
Arch Gen Psych 1991, 48, Schiz Bull 1993, 19, Cecil et al.
Neuropsychopharmacology 1999) and ten papers attempting
to correlate neuroimaging data and clinical progression
(Lieberman et al. Biol Psych 2001, 50, Fannon et al. AJP
2000, 157, Ho et al. AJP 2003, 160, Hoff et al. AJP 2000,
157, Cahn et al. Arch Gen Psych 2002, 59, Gur et al. Arch
Gen Psych 1998, 55, Kasai et al. AJP 2003, 160, Mathalon
et al. Arch Gen Psych 2001, 58, Davis et al. Biol Psych 1998,
43, Jacobsen et al. AJP 1998, 155, Loebel et al. AJP 1992,
149). We focused mainly on the results and limitations on
each one and whether comparisons could be made and
conclusions could be drawn from the studies whithin
each of the domains. No statistical evaluatin was attemp-
tedand the issue of any type of validity was not evaluated.
Results
The weigth of the evidence from clinical psychopathology
and neurocognition points to a progression of cognitive
deficits duting the late premorbid, prodromal and early
first-episode phases of the disorder.
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While there is no evidence of classical neurodegeneration,
there are definite neuropathological deficits. There are
many confounding factors blurring the picture, but never-
theless a suggestion can be made of picture of mainly den-
dritic and synaptic deficits, possibly the result of a mild
neurodegenerative process. Progress in the molecular
techniques and genomic and proteomic analysis will
improve our understanding of the picture.
In the neuroimaging domain, both cross-sectional and
more importantly small longitudinal studies show pro-
gressive brain changes (although a neurodegenerative
explanation of these findings has been challenged by
Weinberger and McClure). Higher resolution longitudinal
studies will clarify the matter. taken together, the func-
tional and spectroscopic studies indicate only a limited
neurodegenerative process in the disorder. Again longitu-
dinal studies will be helpfull. Attempts at correlating neu-
roimaging and clinical progression present some evidence
of it, but not in all studies or across the same brain struc-
tures or in the same clinical or cognitive clusters.
Discussion
The aetilogy of schizophrenia is complex and probably
because of this will remain unknown for some time. It
appears though that the current, prevailing neurodevelop-
mental hypothesis cannot explain the whole gamut of
findings as it appears that its pathophysiology involves
both neurodevelopmental and neurodegenerative proc-
esses.
The histopathology, showing neuronal atrophy and syn-
aptodendritic reductions may be reflecting a limited neu-
rodegenerative process. Neuroimaging studies seem to be
supportive of this. Overall, progressive clinical, neurocog-
nitive, neuropathological and neuroimaging findings
show that neuroprogressive events take place in the pro-
dromal and first-episode perods, suggesting that neurode-
generative processes could intersect with normal
neuromaturational processes, such as myelination and
synaptic prunning, taking place duting adolescence and
early adulthood. This approach could mechanistically
involve apoptotic pathways resulting in neurodegenera-
tion by perturbing the normal synaptic prunning, so tak-
ing place at the prodromal and first-episode phases.
Thus, it appears that schizophrenia could be considered a
limited neurodegenerative process following, temporally,
various neurodevelopmental insults. Certainly though,
more evidence in all domains is needed to establicsh this,
but the trend is quite evident.
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